Blood Chemistry Analyzer 59th Medical Wing

SOL #: PANDHA-25-P-0000Special NoticeSole Source

Overview

Buyer

DEPT OF DEFENSE
Defense Health Agency (Dha)
DEFENSE HEALTH AGENCY
SAN ANTONIO, TX, 78230, United States

Place of Performance

DWG, TX

NAICS

In-Vitro Diagnostic Substance Manufacturing (325413)

PSC

In Vitro Diagnostic Substances, Reagents, Test Kits And Sets (6550)

Set Aside

No set aside specified

Timeline

1
Posted
Mar 5, 2026
2
Action Date
Mar 20, 2026, 9:30 PM

Qualification Details

Fit reasons
  • NAICS alignment with historical contract wins in similar service areas.
  • Scope strongly matches core technical capabilities and delivery model.
Risks
  • Past performance thresholds may require one additional teaming partner.
  • Potential clarification needed on staffing minimums before bid/no-bid.
Next steps

Validate eligibility requirements, assign capture owner, and schedule partner outreach to confirm teaming strategy before submission planning.

Quick Summary

The Defense Health Agency (DHA) HCD-S has issued a Special Notice indicating its intent to award a sole source contract to WERFEN USA LLC for the lease of two Blood Chemistry Analyzers for the 59th Medical Wing in DWG, TX. This notice serves to advise the public of this intent.

Scope of Requirement

The requirement is for two Blood Chemistry Analyzers. The justification for sole source procurement is based on the unique capabilities of Werfen's NEO Iris system, which meets several critical government requirements:

  • Proprietary & Integrated Test Menu: The system must perform a comprehensive panel of tests, including highly specialized Antibody Screen, ABO/Rh, Antibody Titration, Antibody identification, Syphilis, Cytomegalovirus, HIV/HBV/HCV by Nucleic acid testing, WNV, Babesia, Hepatitis B Surface Antigen (HBsAg), Hepatitis B core Antibody (HBcAb), Hepatitis C Antibody (HCV Ab), Human Immunodeficiency virus types 1 and 2 antibody (HIV ½ ab), Human T Lymphotrophic virus types 1 and 2 antibody (HTLV ½ Ab), and Chagas, on a single platform, including FDA-approved NAT tests. It must also test plasma and whole blood.
  • Unique Physical and Infrastructure Requirements: The analyzer must operate without an onsite water source or floor drainage system and adhere to strict physical dimensions (86.6” W x 35.4” D x 73.2” H) due to laboratory space limitations at the 59th MDW.
  • Advanced Sample Integrity and Handling: The system requires capabilities such as clot, bubble, and short sample detection, automatic reflex dilution and repeat testing, and preservation of pediatric samples upon aspiration error, crucial for military trainee populations.
  • Interoperability with Existing Systems: The analyzer must establish a bi-directional interface with the hospital's Electronic Health Record (EHR) and Laboratory Information System (LIS), with a proven interface at other DoD facilities.

Contract & Timeline

  • Type: Special Notice (Intent to Award Sole Source)
  • Proposed Contractor: WERFEN USA LLC
  • Set-Aside: None
  • Response Due: March 20, 2026, 9:30 PM ET
  • Published: March 5, 2026

Response and Challenge

Interested parties who believe they can meet the requirements are invited to submit a statement of capabilities and qualifications. This statement must include company details, a detailed description of capabilities, and evidence demonstrating the ability to meet all outlined requirements. This notice is not a request for competitive proposals; information received will solely determine if a competitive procurement is feasible.

People

Points of Contact

Jorge CanavatiPRIMARY
Joe WellsSECONDARY

Files

Files

No files attached to this opportunity

Versions

Version 1Viewing
Special Notice
Posted: Mar 5, 2026
Blood Chemistry Analyzer 59th Medical Wing | GovScope